Exploring how nanoscale delivery systems affect immune responses
Official title: Harnessing Nanoscale Presentation to Elucidate the Impact of Therapeutic Packaging on Innate Immunity
Funded at Boston University (Charles River Campus) · NIH-11021982 · Data updated 2026-11-12
This study is exploring new ways to create tiny delivery systems that can carry special treatments to help boost your immune system, with the goal of making immunotherapy more effective and personalized for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2025 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $408,750 |
| NIH project number | 1R35GM157326-01 |
| Project ID | NIH-11021982 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with autoimmune conditions or cancers who may benefit from advanced immunotherapy treatments.
✕Less likely to help
Patients who do not have immune-related conditions or are not seeking immunotherapy options may not benefit from this research.
What this research studies
This research investigates how nanoscale delivery systems can be designed to effectively package and deliver various immunomodulatory agents, which can influence immune responses. By focusing on the interactions between these delivery systems and immune cells, the research aims to understand how different structural designs can lead to specific immune outcomes. The approach involves creating synthetic oligonucleotide nanostructures that can be precisely engineered to enhance the effectiveness of immunotherapies. Patients may benefit from improved treatments that are tailored to their unique immune profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies that are personalized based on individual immune responses.
How similar studies have gone: Previous research has shown promise in using nanoscale delivery systems for immunotherapy, indicating that this approach has potential for success.
Where this research is happening
-
Boston University (Charles River Campus)
Boston, United States Active
Researchers
- Principal investigator: Teplensky, Michelle H — Boston University (Charles River Campus)
- Study coordinator: Teplensky, Michelle H
Related research
Other NIH-funded projects on the same topics.
-
How Arousal Changes How We See the World
This grant studies how moments of alertness or mood changes alter how the brain processes what we see.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
Ultra-High Density wearable brain monitoring in real life
Aims to make advanced wearable brain sensors that work in daily life to track brain activity alongside movement, perception, and communication.
-
A new method to image brain activity noninvasively using speckle contrast spectroscopy
A new, noninvasive imaging technique called speckle contrast optical spectroscopy (SCOS) could help measure brain blood flow in people, including those with brain injuries or neurodegenerative conditions.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.